PharmaCyte Biotech Inc (PMCB) — Cash Flow Quality Index

Latest as of January 2026: -1.05x

PharmaCyte Biotech Inc (PMCB) has a Cash Flow Quality Index of -1.05x as of January 2026. Operating cash flow of $-786.85K is below net income of $746.86K, suggesting accrual-heavy earnings not yet converted to cash. Explore PharmaCyte Biotech Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.

Cash Flow Quality Index

-1.05x
Operating CF / Net Income

Operating Cash Flow

$-786.85K
USD

Net Income

$746.86K
USD

Data as of

Jan 2026
Most recent filing

PharmaCyte Biotech Inc Cash Flow Quality Index (2024–2025)

Historical Cash Flow Quality Index for PharmaCyte Biotech Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check PharmaCyte Biotech Inc (PMCB) tangible net worth to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for PharmaCyte Biotech Inc (2024–2025)

Year-by-year earnings quality comparison for PharmaCyte Biotech Inc. For live market cap and the full company financial profile, see PharmaCyte Biotech Inc market capitalisation.

Year Quality Index Operating CF (USD) Net Income YoY Change
2025 -0.10x $-2.98 Million $30.66 Million ▲ +98.5%
2024 -6.45x $-2.15 Million $333.76K
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.